榮昌生物(09995.HK)與Vor Bio達成合作 泰它西普海外授權交易總額或超42億美元
格隆匯6月26日丨榮昌生物(09995.HK)發佈公吿,2025年6月25日, (i)公司及Vor Biopharma Inc.(“Vor Bio”)訂立許可協議(“許可協議”),據此,公司將具有自主知識產權的泰它西普(“許可產品”)有償許可給Vor Bio,Vor Bio將獲得在除大中華區(即中國大陸、中國香港、中國澳門及中國台灣)以外的全球範圍(“許可範圍”)內開發和商業化的獨家權利,以及(ii)煙台榮普股權投資合夥企業(有限合夥)(“榮普合夥”,其由公司全資持有)及Vor Bio訂立證券購買協議(“證券購買協議”),據此,Vor Bio將向榮普合夥發行認股權證,作為公司向Vor Bio授予許可協議項下權利的部分對價。
根據許可協議及在其條款及條件的規限下,(i)Vor Bio應向公司及榮普合夥支付總價值1.25億美元的代價,其中包括公司將從Vor Bio取得4,500萬美元的首付款和Vor Bio將向榮普合夥發行價值8,000萬美元的認股權證(“認股權證”)(假設充分行使認股權證,持有人可認購Vor Bio 3.2億股的普通股,約佔Vor Bio經擴大總髮行股本的23%);(ii)基於臨牀開發進度及上市後的銷售情況,Vor Bio應向公司支付最高可達41.05億美元的數個潛在適應症的里程碑付款;及(iii)Vor Bio將向公司支付達到實際年淨銷售額高個位數至雙位數比例的銷售提成。公司將與Vor Bio設立聯合戰略委員會,以協調許可產品在全球範圍內的開發和商業化。
根據許可協議,Vor Bio同意向榮普合夥發行價值8,000萬美元的認股權證,作為公司向Vor Bio授予許可協議項下權利的部分對價。根據證券購買協議及認股權證的條款,Vor Bio同意向榮普合夥發行認股權證,據此,榮普合夥有權認購Vor Bio3.2億股的普通股,行權價格為每股0.0001美元。在Vor Bio股東會批准發行認股權證所涉股份,公司完成中國監管機構要求的相關批准,以及Vor Bio完成一項旨在增加Vor Bio已授權但未發行普通股股份數量的章程修訂後,榮普合夥可根據認股權證的條款行使認股權證。
公吿表示,許可協議及證券購買協議的訂立將加速泰它西普的海外市場拓展,為全球患者提供創新治療方案,有助於提升公司品牌價值和國際影響力。通過建立合作伙伴關係,公司可加速產品全球開發進程,獲得可觀的里程碑付款及銷售提成,增強公司現金流的同時分散研發風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.